Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity

C. R. Smith, J. J. Lipsky, P. S. Lietman

Research output: Contribution to journalArticle

Abstract

We have reviewed our data from 391 patients entered into three prospective, double-blind studies of aminoglycosides and evaluated 127 cases to determine whether aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events. The cases selected for evaluation included all patients treated for greater than 3 days (mean, 7.7 days) who had serial creatinine determinations and were able to cooperate with serial bedside audiograms (250 to 8,000 Hz). Patients received either gentamicin, tobramycin, or amikacin. Drug dosage was altered to keep serum levels 1 h after administration between 5 and 10 μg/ml (gentamicin or tobramycin) or 20 and 40 μg/ml (amikacin). The investigators evaluating auditory toxicity and nephrotoxicity were blind to the aminoglycoside being administerd. The incidence of auditory toxicity in the nephrotoxic group (18.2%) was not significantly different from that in the nonnephrotoxic group (15.2%) (P = 0.75; Fisher exact test). There was no statistical difference between the nephrotoxic and auditory toxic groups in patient age, total dose of aminoglycoside, initial creatinine level, duration of therapy, or concurrent use of furosemide or cephalothin. We conclude that aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events when the drug is administered for approximately 7 days and when aminoglycoside levels are maintained within a predefined range.

Original languageEnglish (US)
Pages (from-to)780-782
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume15
Issue number6
StatePublished - 1979

Fingerprint

Aminoglycosides
Tobramycin
Amikacin
Gentamicins
Creatinine
Cephalothin
Poisons
Furosemide
Double-Blind Method
Pharmaceutical Preparations
Research Personnel
Incidence
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. / Smith, C. R.; Lipsky, J. J.; Lietman, P. S.

In: Antimicrobial Agents and Chemotherapy, Vol. 15, No. 6, 1979, p. 780-782.

Research output: Contribution to journalArticle

Smith, C. R. ; Lipsky, J. J. ; Lietman, P. S. / Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. In: Antimicrobial Agents and Chemotherapy. 1979 ; Vol. 15, No. 6. pp. 780-782.
@article{75e28ebd2b1b4dcdbf25105f0f0fdea9,
title = "Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity",
abstract = "We have reviewed our data from 391 patients entered into three prospective, double-blind studies of aminoglycosides and evaluated 127 cases to determine whether aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events. The cases selected for evaluation included all patients treated for greater than 3 days (mean, 7.7 days) who had serial creatinine determinations and were able to cooperate with serial bedside audiograms (250 to 8,000 Hz). Patients received either gentamicin, tobramycin, or amikacin. Drug dosage was altered to keep serum levels 1 h after administration between 5 and 10 μg/ml (gentamicin or tobramycin) or 20 and 40 μg/ml (amikacin). The investigators evaluating auditory toxicity and nephrotoxicity were blind to the aminoglycoside being administerd. The incidence of auditory toxicity in the nephrotoxic group (18.2{\%}) was not significantly different from that in the nonnephrotoxic group (15.2{\%}) (P = 0.75; Fisher exact test). There was no statistical difference between the nephrotoxic and auditory toxic groups in patient age, total dose of aminoglycoside, initial creatinine level, duration of therapy, or concurrent use of furosemide or cephalothin. We conclude that aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events when the drug is administered for approximately 7 days and when aminoglycoside levels are maintained within a predefined range.",
author = "Smith, {C. R.} and Lipsky, {J. J.} and Lietman, {P. S.}",
year = "1979",
language = "English (US)",
volume = "15",
pages = "780--782",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity

AU - Smith, C. R.

AU - Lipsky, J. J.

AU - Lietman, P. S.

PY - 1979

Y1 - 1979

N2 - We have reviewed our data from 391 patients entered into three prospective, double-blind studies of aminoglycosides and evaluated 127 cases to determine whether aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events. The cases selected for evaluation included all patients treated for greater than 3 days (mean, 7.7 days) who had serial creatinine determinations and were able to cooperate with serial bedside audiograms (250 to 8,000 Hz). Patients received either gentamicin, tobramycin, or amikacin. Drug dosage was altered to keep serum levels 1 h after administration between 5 and 10 μg/ml (gentamicin or tobramycin) or 20 and 40 μg/ml (amikacin). The investigators evaluating auditory toxicity and nephrotoxicity were blind to the aminoglycoside being administerd. The incidence of auditory toxicity in the nephrotoxic group (18.2%) was not significantly different from that in the nonnephrotoxic group (15.2%) (P = 0.75; Fisher exact test). There was no statistical difference between the nephrotoxic and auditory toxic groups in patient age, total dose of aminoglycoside, initial creatinine level, duration of therapy, or concurrent use of furosemide or cephalothin. We conclude that aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events when the drug is administered for approximately 7 days and when aminoglycoside levels are maintained within a predefined range.

AB - We have reviewed our data from 391 patients entered into three prospective, double-blind studies of aminoglycosides and evaluated 127 cases to determine whether aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events. The cases selected for evaluation included all patients treated for greater than 3 days (mean, 7.7 days) who had serial creatinine determinations and were able to cooperate with serial bedside audiograms (250 to 8,000 Hz). Patients received either gentamicin, tobramycin, or amikacin. Drug dosage was altered to keep serum levels 1 h after administration between 5 and 10 μg/ml (gentamicin or tobramycin) or 20 and 40 μg/ml (amikacin). The investigators evaluating auditory toxicity and nephrotoxicity were blind to the aminoglycoside being administerd. The incidence of auditory toxicity in the nephrotoxic group (18.2%) was not significantly different from that in the nonnephrotoxic group (15.2%) (P = 0.75; Fisher exact test). There was no statistical difference between the nephrotoxic and auditory toxic groups in patient age, total dose of aminoglycoside, initial creatinine level, duration of therapy, or concurrent use of furosemide or cephalothin. We conclude that aminoglycoside-induced auditory toxicity and nephrotoxicity are independent events when the drug is administered for approximately 7 days and when aminoglycoside levels are maintained within a predefined range.

UR - http://www.scopus.com/inward/record.url?scp=0018774578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018774578&partnerID=8YFLogxK

M3 - Article

C2 - 475363

AN - SCOPUS:0018774578

VL - 15

SP - 780

EP - 782

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -